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Although IgA nephropathy (IgAN) is the most common form
of primary glomerulonephritis worldwide, our understanding
of the pathogenesis of this complex disease remains limited.
IgA nephropathy may appear with a variety of clinical
presentations, a number of different clinical and
histopathologic risk factors for progressive renal disease, and
a very variable course over time. Thus, it is not surprising that
a single therapeutic treatment plan has not been established.
Many of the studies dealing with IgAN are retrospective, lack
statistical significance, or have confounding designs, which
hinder their general acceptance. Nevertheless, a number of
well-designed studies have been performed. This paper
reviews currently available therapeutic options for IgAN.
It attempts to address several important questions: Why
do we treat patients with IgAN? How do we decide which
patients should be treated? What are the general treatment
guidelines for all IgAN patients? What is the role of specific
therapy such as fish oils, tonsillectomy, and
immunosuppression in the treatment of patient with IgAN? It
also addresses several on-going trials and goals for future
therapeutic studies for IgAN patients.
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IgA nephropathy (IgAN) remains one of the most common
forms of idiopathic glomerular diseases in almost every
developed country. Its protean manifestations range from
asymptomatic microhematuria and proteinuria to massive
edema with the nephrotic syndrome, or fulminant rapidly
progressive renal failure with crescentic glomerulonephritis.
Up to 30% of patients will progress to end-stage renal disease
(ESRD) by 20 years. Unfortunately, the treatment of this
common renal disease remains a dilemma. There are several
major reasons for the lack of a single clear treatment strategy
applicable to all patients with IgAN. First, the pathogenesis of
IgAN remains unknown. Many potentially pathogenic
abnormalities have been associated with the disease. There
are clear immune complex deposits containing IgA in the
glomeruli. Genetic abnormalities of the renin–angiotensin
system (RAS) and other mediators of vascular and inflam-
matory responses have been documented. Abnormalities of
galactosylation may occur at the hinge region of the IgA
molecule. There may be altered binding of IgA to mesangial
cells. Nevertheless, the exact mechanism of how immune
IgA-containing deposits ultimately lead to proliferation and
sclerosis of glomeruli remains an enigma. This makes
designing a specific therapy directed at the etiology of the
disease impossible. Another problem for those treating
patients with IgAN is the extreme variability of presentation
and course. Some patients maintain only isolated urinary
findings for years, whereas other patients are progressing to
end-stage renal failure. Determining exactly who is likely to
develop renal failure over time based on clinical, epidemio-
logic, and histologic renal findings remains a challenge. Even
among those who do have progressive disease, the course is
often indolent. While the use of aggressive immunosuppres-
sive treatment strategies may seem reasonable in patients
with crescentic glomerulonephritis and a rapidly progressive
course, it may be far less appealing to clinicians dealing with
patients with only mild proliferative glomerular lesions and
only a slow change in glomerular filtration rate (GFR) over
time. Nevertheless, many treatment trials have been perfor-
med in patients with IgAN. Some of these studies are large,
controlled, randomized, and provide valuable information.
At present, a reasonable approach to the treatment of this
disease might include searching for the answers to five
questions. First, why are we treating the disease? Second, who
warrants therapy for IgAN, that is, who is the high-risk
patient? Third, what treatment strategies should be applied to
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all patients with this glomerular disease? Fourth, what
specific disease-modifying therapies should be applied to
only some patient groups with IgAN? Finally, how will we
acquire new data to help answer our questions regarding the
best therapy of IgAN?
WHY DO WE TREAT IgAN?
IgAN is a very frequent glomerular disease. It accounts for
approximately 30–40% of patients undergoing renal biopsy in
Asia, 15–20% in Europe, and 5–10% in North America. It is
unclear if these differences are related to true genetic
susceptibility differences or geographic differences in urina-
lysis screening practices and selection differences in indica-
tions for renal biopsy. Clearly, preventing renal failure has
been the major focus of therapy for nephrologists treating
patients with IgAN. Although the exact proportion of
patients who progress to renal failure is very variable, many
series report that a significant percentage of patients will
develop ESRD by 10 years. The percentage increases to
25–30% by 20 years and is likely to be significantly higher at
30 years. Many patients with IgAN are young at clinical
presentation. Renal survival rates of 30 years and longer are
very reasonable concerns for patients with this disease. Thus,
preventing progressive renal disease is a valid concern for
everyone dealing with the disease.
However, there are other equally important treatment
concerns in this disease as well. Cardiovascular complications
are a major cause of morbidity and the major cause of
mortality in patients with chronic kidney disease. Moreover,
a number of well-performed large, epidemiologic studies
clearly show that patients with chronic kidney disease are far
more likely to die of cardiovascular events than reach
ESRD.1,2 The IgAN patient with a reduced GFR, hyper-
tension, dyslipidemia, and other cardiovascular risk factors
is clearly at risk for a cardiovascular event during a slow
indolent course to ESRD. Furthermore, almost every risk
factor for cardiovascular disease (i.e. hypertension, dyslipi-
demia, or cigarette smoking) has also been shown to be a
risk factor for progression to renal failure. Thus, treatment
of these risk factors should be a high priority in the care of
patients with IgAN.
WHICH PATIENTS DO WE TREAT?
The patient who is most likely to progress to chronic kidney
disease and ultimately ESRD may be the patient most likely
to derive the most benefit from therapy. This is especially true
if the potential therapies have offsetting side effects that must
be carefully weighed into the benefit–risk ratio. A number of
epidemiologic, clinical, and histologic features have been
associated with a more progressive course in IgAN. Some
have been integrated into formulae to predict renal outcome.
Clinical features at either presentation or at time of renal
biopsy predictive of progression include higher degrees of
proteinuria, reduced GFR, persistent microhematuria, and
presence of hypertension3–5 (Manno C et al. J Am Soc Nephrol
2005; 16: 523A; abstract). For example, one long-term study
followed 298 IgAN patients with a mean baseline serum
creatinine of 1.54 mg/dl, creatinine clearance of 76 ml/min,
and initial urinary protein excretion of 2.3 g/day.4 Only two
of 10 variables by multivariate analysis independently
predicted progression of renal disease: higher mean blood
pressure (BP) and greater amounts of proteinuria. The
change in GFR in ml/min/year decreased by 0.2 for each
1 mm Hg increase in mean arterial pressure above 97 mm Hg
and by 0.3 for each 200 mg/day increase in urinary protein
excretion above 200 mg/day.4 Other investigators have found
greater value in evaluating certain clinical features after 1 year
of maximal therapeutic intervention, rather than at the time
of presentation. In two study populations, the Mayo Clinic
group found that the degree of proteinuria and reduction in
GFR at 1 year were highly predictive of progressive renal
disease.5 Thus, patients with proteinuria of 0.5–1 g/day at
1 year fared far worse than those with less than 0.5 g/day, and
those with greater amounts did even worse. It is interesting
that this level of proteinuria, which would be considered a
favorable prognostic feature for other glomerular diseases,
(i.e. focal glomerulosclerosis or membranous nephropathy),
is highly predictive of a poor ultimate outcome in IgAN.
Likewise, patients with a serum creatinine between 2 and
2.9 mg/dl at 1 year did worse than those patients with a
serum creatinine o2 mg/dl. Recently, new clinical features,
such as the level of uric acid, have been found to be inde-
pendent risk factors for progression. The correlation between
serum uric acid and underlying pathology was examined in
one study of 212 IgAN patients. Serum uric acid levels
correlated independently and directly with the severity of
tubulointerstitial lesions, and thus with a worse prognosis.6
A recent abstract also found serum uric acid levels to be an
independent risk factor for progression of renal disease in 386
patients with IgAN (Chin HJ et al. J Am Soc Nephrol 2005; 16:
522A; abstract). After adjusting for all known confounding
factors (age, gender, body mass index, creatinine, and choles-
terol), serum uric acid level remained a significant risk factor
for progression by multivariate analysis (P¼ 0.02) in patients
with initial normal serum creatinine and BP.
The finding of certain histologic features on biopsy such as
glomerulosclerosis, crescents, and interstitial fibrosis also
predict a worse outcome. It is clear from several large studies
that these risk factors for progression are cumulative, and
as such, the patient with multiple risk factors is at higher
risk for developing renal impairment.3 This may help
guide decisions regarding treatment, and more specifically,
which patients should not be treated. For example, patients
with marked reduction in GFR, heavy proteinuria, and
extensive glomerulosclerosis are likely to progress to ESRD
and less likely to benefit from immunosuppression designed
to modulate glomerular inflammatory processes.
GENERAL TREATMENT RECOMMENDATIONS FOR ALL
IGAN PATIENTS
Certain therapeutic interventions have appeared beneficial in
almost all reported trials in IgAN. As hypertension is a risk
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factor for progression in IgAN and virtually all renal diseases,
optimal control would be ideal. A reasonable goal is to aim
for BPs p125/75 130/80 mm Hg. A 3-year randomized
controlled trial found that IgAN patients with a mean BP of
136/76 mm Hg had reductions in creatinine clearance over
3 years, whereas those with a mean BP of 129/70 mm Hg
maintained stable renal function over the same time.7
Likewise, a number of trials have shown that blockade of
the RAS with either ACE inhibitors (ACEI) or angiotensin II
receptor blockers (ARB) is beneficial in IgAN patients. In a
retrospective study of IgAN patients in the Toronto registry,
use of ACEI to control hypertension lowered the annual loss
of renal function to the same level as normotensive IgAN
patients. In contrast, those treated with other antihyper-
tensive drugs had a greater annual loss of GFR.8 Further
evidence of the renoprotective effect of ACEI is provided by
a recent randomized controlled trial, which demonstrated
improved renal survival in IgAN patients receiving enalapril
compared to those receiving other antihypertensive drugs
despite equivalent BP control (o140/90 mm Hg). The pri-
mary end point of 50% increase in baseline serum creatinine
was reached in only 13% of the patients treated with enalapril
compared to 57% of those patients treated with alternate
medications.9
Recent studies have suggested benefit from the combina-
tion of ACEI and ARB in patients with glomerular diseases
including IgAN. Many studies demonstrate a greater reduc-
tion in proteinuria with combination therapy compared to
monotherapy with ACEI or ARB at similar levels of BP
control.10 One such study was the COOPERATE trial, a large
randomized study of 336 patients with non-diabetic renal
disease, in which 50% of subjects had IgAN.11 Patients were
randomized to maximal antiproteinuric ACE inhibition with
trandolapril, maximal ARB therapy with losartan, or dual
ACEI–ARB therapy. Not only was proteinuria reduced further
with combination therapy at equivalent BP levels, but
progression to renal failure was also significantly reduced.
There are many questions about such treatments: Is the
optimal antiproteinuric dose of an ACEI or ARB in any
way related to the antihypertensive dose of the drug? Are
more potent drugs of these classes of antihypertensives
more effective in preventing renal disease? What is the role of
diuretics in potentiating the antiproteinuric and renoprotec-
tive effect of the medications? What is the role of aldosterone
blockade here? Nevertheless, the evidence supports use of
blockade of the RAS in all hypertensive and probably all
proteinuric patients with IgAN.
The evidence for antihyperlipidemic therapy in slowing
progression to renal failure is not nearly as firmly established
as that for BP control. However, there is data from a
well-performed meta-analysis of renal disease in general, and
a number of studies showing benefit in slowing renal progres-
sion.12,13 Moreover, given the overwhelming data on statin
therapy in reducing the risk of cardiovascular disease in high-
risk patients, and the high-risk nature of the chronic kidney
disease population, a strong argument can be made to use an
HMG Co-A reductase inhibitor in all IgAN patients with
dyslipidemia, hypertension, and other cardiovascular risks
(smoking, family history, etc.). Whether alterations in diet
benefit these patients is even less clear, but certainly modest
protein intake reduction is reasonable in patients with this
glomerular disease and significant proteinuria.
THE ROLE OF TONSILLECTOMY AND FISH OILS IN IGA
NEPHROPATHY
Several retrospective studies have analyzed the role of tonsil-
lectomy in the treatment of IgAN. Most contain a small
number of patients, are non-randomized uncontrolled trials,
and provide conflicting data. A retrospective study from
Germany reviewed the renal outcome in 55 patients with
IgAN, 16 of whom had a prior tonsillectomy. Tonsillectomy
did not have an independent impact on renal survival 10
years after biopsy.14 A Japanese study of 329 patients with
IgAN found tonsillectomy to be an independent factor in
predicting remission of clinical findings and lack of renal
progression.15 A more recent retrospective study from Japan
analyzed 118 patients with IgAN followed over 20 years.16
Forty-eight of these patients had a prior tonsillectomy. Renal
survival at 240 months was 90% for the tonsillectomy group
and 64% for the group without tonsillectomy. By multi-
variate analysis, tonsillectomy had a significant impact on
renal outcome. However, renal survival curves only diverged
between the two groups at greater than 10 years from biopsy.
It is clear that none of these studies contain populations
large enough for epidemiologic analysis, none are rando-
mized controlled or prospective, and they may only apply
to patients within a given geographic area. At present, there
is insufficient data to recommend tonsillectomy for IgAN
patients. Those with recurrent bouts of tonsillitis may benefit,
but if so, only at some time in the distant future.
The role of fish oils in preventing progressive renal disease
in IgAN remains no less controversial. Fish oils have been
shown to possess a number of potential benefits in preventing
cardiovascular events in high-risk populations. There is good
rationale for the use of fish oils in IgAN: they have been
shown to inhibit cell growth and proliferation, inhibit renal
inflammation, reduce serum lipids, decrease BP, and reduce
proteinuria and glomerular injury in several animal models
of glomerular disease.17 However, they do have a number of
detracting side effects including a fishy odor, inconvenience
of large medication dosages, and expense. Moreover, they
may delude patients into feeling that they are definitively
treating their renal disease at the expense of instituting other
more effective therapies. A number of studies have evaluated
the role of fish oils in IgAN. A Japanese study of 20 patients
followed for 1 year demonstrated stabilization of renal
function with fish oil use.18 Conversely, an Australian study
of 37 patients found no benefit on the renal outcome over
2 years.19 A controlled, meticulously performed, randomized
trial of 32 patients with IgAN and moderately reduced GFR
from Sweden found that fish oils led to greater reduction in
GFR than corn oil (placebo), and that the fish oils provided
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no benefits.20 However, a randomized, controlled study of
106 IgAN patients from the Mayo Clinic showed a clear
benefit from fish oils. The patients had proteinuria of 41 g/
day, impaired renal function (serum creatinine up to
3 mg/dl) and 60% were hypertensive. They were treated with
1.8 g of eicosapentaenoic acid and 1.2 g of docosahexaenoic
acid or placebo for 2 years and then followed for 5 years. At
both short- and longer-term follow-up, fewer patients in the
fish oil group compared to placebo had a 50% increase in
plasma creatinine (6 vs 33%, respectively). The fish oil arm
also showed a slower decline in the GFR, and less death,
dialysis, or transplantation.21,22 A subsequent randomized
trial comparing high-dose fatty acids vs low-dose (or ‘stan-
dard dose’) fatty acids in a similar high-risk IgAN population
did not show any additional renoprotective effect in the
higher dose group.23 Most recently, a randomized, controlled
blinded trial of almost 100 patients (age o40 years GFR
450 ml/min, urine protein:creatinine ratio 40.5) were
randomized to receive either omega-3 fatty acids (4 g/day)
or alternate day prednisone or placebo for 2 years (Hogg R
et al. J Am Soc Nephrol 2003; 14: 751A; abstract; Hogg R et al.
J Am Soc Nephrol 2004; 15: 337A; abstract). At the end of 2
years, there was no difference in the primary end point of
decline in GFR to less than 60% of baseline (14 treatment
failures – two with prednisone, eight with fish oils, and four
with placebo). Unfortunately, even with 100 patients,
randomization was not equal and the fish oil group had
higher levels of proteinuria at study initiation portending a
worse renal prognosis regardless of treatment category. Given
these conflicting data, one cannot recommend fish oil as
beneficial in preventing progressive renal failure in this
population. However, one cannot disprove that it may have a
beneficial effect either on the renal disease or cardiovascular
outcomes. At present, it is reasonable to let patients decide
for themselves whether the side effects and cost of fish oil
therapy outweigh potential unproven renal benefits. Fish
oils should not be used in lieu of other proven or suggested
therapies.
WHAT IS THE ROLE OF CORTICOSTEROIDS AND OTHER
IMMUNOSUPPRESSIVES?
A number of studies have examined the role of cortico-
steroids in patients with IgAN. Corticosteroids have provi-
ded dramatic remissions of the nephrotic syndrome in those
IgAN patients with normal appearing glomeruli, only
mesangial IgA deposits, and diffuse foot process effacement
on electron microscopy. These patients with the so-called
‘IgAN minimal change disease’ clearly have a very different
disease than most IgAN patients, and are really a minimal
change disease variant. In other IgAN populations, cortico-
steroids have given mixed results. Some studies have sugges-
ted benefit, whereas others have not. Most of the studies are
not prospective, randomized, or controlled, and have not
provided conclusive results. One randomized controlled
trial examined 90 IgAN patients (baseline serum creatinine
o1.5 mg/dl) randomized to receive either oral prednisone
tapered over 2 years or placebo.24 Renal survival was identical
(85%) at 84 months, although the proteinuria declined more
in the steroid group. An exception to these mixed results
comes from the well-designed, randomized, controlled trial
by Pozzi et al. In this study, 86 IgAN patients (baseline Serum
creatinine o1.5 mg/dl and 1–3.5 g/day proteinuria), were
randomized to receive six cycles of pulse methylprednisolone
at the beginning of each month followed by alternate day
corticosteroids vs placebo. After 6 years of follow-up, fewer
patients in the steroid group reached the end point of a
50% increase in serum creatinine.25 After 10 years of follow-
up, renal survival in the steroid group was 97 vs 53% in the
placebo group, with improvement favoring steroids regard-
less of histologic class of IgAN.26 The short course of
treatment and alternate day therapy led to few side effects
and is a rather benign regimen. It is unknown whether
replacing the solumedrol pulses with high-dose oral cortico-
steroids would work as well. Likewise, it is also unknown
whether tighter BP control of both groups with universal use
of blockers of the RAS would have minimized any of the
benefits of steroids. Nevertheless, this well-designed trial
strongly suggests a role for a 6-month trial of corticosteroids
in IgAN patients with urinary protein excretion 41 g/day yet
preserved renal function. A recent meta-analysis supports the
use of corticosteroids in reducing proteinuria and preventing
progression to ESRD.27
The use of other immunosuppressive medications in IgAN
patients has not been well evaluated in controlled, prospec-
tive, randomized populations in sufficient numbers to define
a clear outcome. A retrospective analysis of 74 IgAN patients
followed for 10 years suggested that long-term azathioprine
combined with low-dose prednisone did not alter the
clinical course compared to untreated controls. However, in
a subgroup of patients with heavy proteinuria (43 g/day)
and baseline serum creatinine 1.4–2.5 mg/dl, this immuno-
suppression regimen was associated with a decreased risk
of doubling of the serum creatinine compared to controls
(27 vs 78%) and delayed progression to ESRD (17 vs 55%,
respectively).28 However, this was not a prospective trial.
A recent prospective, controlled randomized trial of 38 IgAN
patients does suggest benefit from oral cyclophosphamide
plus steroids given for 2 months followed by azathioprine
therapy for 2 or more years. The 5-year renal survival in the
treated group was 72 vs 6% in the control group.29 This study
may be faulted for less than ideal BP control and insufficient
use of medications that block the RAS, the unusually poor
survival rate of the placebo group, and small number
of patients. Others have suggested a clear beneficial role
of cyclophosphamide in crescentic glomerulonephritis when
compared to the course of historical controls.30 Certainly,
cyclophosphamide has dramatically changed the course of
other forms of rapidly progressive crescentic glomerulo-
nephritis. However, use of alkylating agents and long-term
immunosuppression is not without side effects. At present, it
is reasonable to use cyclophosphamide with corticosteroids
for IgAN patients with true crescentic rapidly progressive
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glomerulonephritis. It may also be reasonable to try this form
of therapy in some IgAN patients with significant proteinuria
and deteriorating renal function. However, more supportive
evidence is required before this treatment can be widely
accepted.
Mycophenolate mofetil has been used in four major trials
in IgAN. The results are mixed. In one of these trials,
33 patients with a mean serum creatinine of 1.4 mg/dl
and urinary protein excretion of 1.6 g/day were placed on a
low-salt diet and an ACEI and then randomized to receive
either mycophenolate (2 g daily) or placebo for 2 years. There
was no difference in the change in creatinine or urinary
protein excretion between the groups. Clearly, this study
was underpowered to detect such differences.31 A second
study examined a subset of IgAN patients with proteinuria
greater than 2 g/day that were randomized to receive either
mycophenolate or prednisone. Both proteinuria and choles-
terol decreased to a greater extent and serum albumin rose to
a higher level in the mycophenolate group. Serum creatinine
was higher in the prednisone group at 72 weeks (Chen Z et al.
J Am Soc Nephrol 2001; 12: 66A; abstract).32 A third study
showed a greater reduction of proteinuria in patients treated
with mycophenolate compared to placebo, but no difference
in serum creatinine.33 Finally, the fourth study was a blinded,
randomized controlled trial of mycophenolate vs placebo in
patients with progressive IgAN.34 All patients had optimal
BP control with ACEI. Patients had a mean creatinine of
2.4 mg/dl and greater than 2.5 g/day proteinuria on average.
This trial was prematurely terminated after enrolling only
40 patients owing to the high rate of progression in both
arms of the study. Clearly, mycophenolate is not a panacea
for patients with severe reductions in GFR and marked
proteinuria. Thus, despite promising results in large rando-
mized controlled trials in other glomerular diseases, the
evidence for the use of mycophenolate in IgAN is totally
inconclusive.35 Any use of this medication in IgAN should
currently be considered investigational. Likewise, newer
immunosuppressives such as leflunimide, rituximab, and
sirolimus should be considered experimental therapies at this
point.
WHAT DATA WILL ON-GOING TRIALS PROVIDE?
Most patients with IgAN will benefit from BP control,
blockade of the RAS, and other non-immunosuppressive
measures. This therapy also has the added benefit of reducing
the risk of cardiovascular disease in this population, many of
whom will progress to chronic kidney failure. It is also clear
that we do not have strong evidence for the general use of
steroids or other immunosuppressive medications in many
IgAN patients. However, the lack of data does not imply that
these therapies are ineffective; it merely means that we do not
have the studies to prove they are effective. New studies
would be helpful. An on-going prospective Japanese study of
tonsillectomy combined with steroids vs steroids alone may
shed light on this particular modality. Preliminary data
suggest improvement in hematuria and proteinuria in the
tonsillectomy group, but no difference in doubling of the
serum creatinine at 24 months (Komatsu H et al. J Am
Soc Nephrol 2005; 16: 523A; abstract). However, given the
published data, it would appear that prolonged follow-up
will be necessary to show if there is any benefit of tonsil-
lectomy. Currently, a randomized, blinded multicenter
controlled trial of mycophenolate mofetil vs placebo is under-
way in the United States. If recruitment is large and there is
sufficient follow-up, the role of this agent may be clarified. It
is clear that we need more, large, well-designed collaborative
trials to determine whether there is a role for steroids and
other immunosuppressives in the majority of IgAN patients
who slowly progress to renal failure over many years.
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